FDA approves Rasonque for pancreatic cancer
https://www.yahoo.com/news/science/articles/f...50455.html
Patients who received Rasonque lived a median of 13.2 months, compared with 6.7 months for those treated with chemotherapy. The drug reduced the risk of death by 60 percent and also delayed disease progression.
"This is not a cure, it's one more option for these patients," said Dr. Pashtoon Kasi of City of Hope Orange County, a California-based cancer center. "But it's the best option we've ever had."
Rasonque was associated with fewer severe side effects than chemotherapy. Common ones included rash, diarrhea, mouth sores, nausea, fatigue, vomiting and abdominal pain. While the treatment is not a cure, specialists said the results represent a significant advance for patients with metastatic pancreatic cancer, a disease that has long had limited treatment options.
https://www.yahoo.com/news/science/articles/f...50455.html
Patients who received Rasonque lived a median of 13.2 months, compared with 6.7 months for those treated with chemotherapy. The drug reduced the risk of death by 60 percent and also delayed disease progression.
"This is not a cure, it's one more option for these patients," said Dr. Pashtoon Kasi of City of Hope Orange County, a California-based cancer center. "But it's the best option we've ever had."
Rasonque was associated with fewer severe side effects than chemotherapy. Common ones included rash, diarrhea, mouth sores, nausea, fatigue, vomiting and abdominal pain. While the treatment is not a cure, specialists said the results represent a significant advance for patients with metastatic pancreatic cancer, a disease that has long had limited treatment options.
8
